Quantum BioPharma Receives FDA Clearance for Phase 2 MS Trial
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Quantum BioPharma announced it received clearance from the FDA to proceed with a Phase 2 clinical trial of Lucid-21-302, known as Lucid-MS, for multiple sclerosis. The company subsequently entered into a Study Start-Up Agreement with Thermo Fisher Scientific to implement the trial.
From finanznachrichten.de
Why it matters
The clearance and the contract milestone mark an important step in the clinical development of Lucid-MS. This advancement validates the drug's pipeline and reduces the research and development risk for Quantum BioPharma.
From finanznachrichten.de
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- QUANTUMSpeculative
The successful regulatory clearance and contract initiation could validate the drug pipeline and potentially affect future investment or funding.